Montelukast Combix (Montelukast)

Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1 on airway smooth‑muscle cells, mast cells and eosinophils. By preventing leukotriene D4 from binding, it stops bronchoconstriction, mucus production and inflammatory cell recruitment, thereby reducing airway hyper‑responsiveness and allergic inflammation.

The appropriate dose of Montelukast Combix is determined by the prescribing healthcare professional based on the patient’s age, weight, disease severity and response to therapy. Dosing recommendations are provided in the product label and should be followed exactly as instructed by the prescriber.

Safety data for montelukast in pregnancy are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies any potential risk to the fetus. Caution is also advised during breastfeeding, and a clinician should evaluate the risk‑benefit ratio.

To request Montelukast Combix, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids and long‑acting beta‑agonists. It is particularly useful for patients with aspirin‑sensitive asthma or those who need additional control of allergic rhinitis, but it does not replace rescue bronchodilators for acute attacks.

Montelukast Combix tablets should be stored at room temperature, below 25 °C, in the original blister pack or container to protect them from moisture and light. Keep the medication out of reach of children and do not use it after the expiration date.

Montelukast Combix is taken orally, usually once daily in the evening, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless the prescriber provides specific instructions.

Although uncommon, serious adverse reactions to Montelukast can include severe allergic responses such as rash, angioedema or anaphylaxis, and neuropsychiatric events like mood changes, depression or suicidal thoughts. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast Combix should be avoided in individuals with known hypersensitivity to montelukast or any of the tablet’s excipients. It is also not suitable for treating acute asthma attacks and should not replace rescue inhalers. Patients with severe hepatic impairment should use it only under close medical supervision.